CClinicalTrials.gg
Active, not recruitingNCT06387316Updated Apr 29, 2024

Cephalic Phase Responses to Nutritive and Non-Nutritive Sweeteners

An interventional study of No Oral Stimulation and Oral water stimulation in Pre Diabetes, sponsored by Purdue University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Purdue University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study will focus on changes in blood sugar in response to tasting different types of sweeteners using continuous glucose monitoring (CGM) technology.

Read the detailed description

Participants will be recruited through posting of advertisements about the study. Flyers will be posted on and off campus. Individuals interested in the study will contact the researchers and an initial appointment will be scheduled.

First Lab Visit (Day 1):

Consent and Instruction: Researchers will explain the study procedures, including the use of continuous glucose monitoring (CGM), home-based taste testing and wearing the Fitbit activity tracker. Participants will complete a short questionnaire (screening questionnaire) that elicits demographic, health and activity information. Participants can choose to decline to answer any questions they prefer not to answer. Researchers will determine if participants meet eligibility criteria and participants will then decide if they want to participate. A CGM device will be placed on the participant's arm to monitor glucose levels continuously. Placing the monitor involves putting an egg-shaped plastic container (about the size of a golf ball) on the back of one arm and a button is pushed and this presses the sensor on the arm. It is held on by adhesive. It is like applying a band aid though there is a hair-like flexible fiber that is pressed into the skin (not into a vein). The participant feels little more than mild pressure - far less than a needle stick. Participants will be given individually portioned, labeled sample solutions including a nutritive sweetener, non-nutritive sweetener, a non-sweet control stimulus (salt) and just water along with commercially available no sodium rice cakes (cut to bite-size pieces). Participants will be instructed to place one rice cake sample in their mouth and sip a 5ml oral solution sample and masticate for 15 seconds and expectorate. This will be repeated 3 additional times. With about 15 seconds between samples. This exposure will require about 2 minutes. This will be repeated 4 times a day (before breakfast, before lunch, before dinner and at 8PM) on 8 days. There will be no oral stimulation for 2 days. Participants will be provided with activity recall sheets and instructed to record their sleep patterns, and physical activity for 10 days. This form will only contain an identification code, no personally identifiable information be on the form. Participants will also be asked to wear a Fitbit to monitor activity. This is exactly like wearing a wristwatch.

02

Conditions studied

  • Pre Diabetes

Browse trials for

03

In context

Prediabetic State

999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.

This study's planned enrollment of 30 is below the median of 65 across 844 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Purdue University is the lead sponsor of 168 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Adults aged between 18 to 70 years old will be eligible to participate.
  • Good health and without known medical conditions, including but not limited to, diabetes, cardiovascular diseases, metabolic disorders, and any other chronic conditions that could significantly affect glycemia.
  • No history of major surgeries, organ transplantations, or significant medical interventions that might impact glycemia.
  • No medications that could interfere with glucose metabolism or sweet taste perception. Use of vitamins or contraceptives will be permissible if continued for the 12 days of study participation.
  • No dietary restrictions or sensitivities that prevent them from tasting or swishing sweeteners and rice cakes provided during the study.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Other
    No Oral Stimulation

    No oral stimulation is provided.

    Other: No Oral Stimulation

  • Other
    Oral Water Stimulation

    Oral stimulation with water.

    Other: Oral water stimulation

  • Other
    Oral Salt Stimulation

    Oral stimulation with salt.

    Other: Oral Salt Stimulation

  • Other
    Oral Sucralose Stimulation

    Oral stimulation with sucralose.

    Other: Oral Sucralose Stimulation

  • Other
    Oral Sucrose stimulation

    Oral stimulation with sucrose.

    Other: No Oral Stimulation · Other: Oral Sucrose stimulation

Interventions

  • OtherNo Oral Stimulation

    No oral stimulation

  • OtherOral water stimulation

    Oral water stimulation

  • OtherOral Salt Stimulation

    Oral Salt Stimulation

  • OtherOral Sucralose Stimulation

    Oral Sucralose Stimulation

  • OtherOral Sucrose stimulation

    Oral Sucrose stimulation

06

What researchers measure

Primary outcomes

  1. Blood glucose concentration

    blood glucose concentration measured by continuous glucose monitoring

    Time frame: 10 days

07

Study locations

1 site
  • Purdue University
    West Lafayette, Indiana 47907, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06387316
Lead sponsor
Purdue University
Responsible party
Richard Mattes (Distinguished Professor, Purdue University) — Principal investigator
First posted
Apr 29, 2024
Start date
Mar 26, 2024
Primary completion
Apr 17, 2024
Completion
Mar 30, 2025 (estimated)
Last update
Apr 29, 2024

Study contacts

Richard Mattes, PhD
principal investigator · Purdue University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion